Sign In
to Vote &
Create Storyboards.
 
Neovasc Inc. (TSXV: NVC) has announced that a review of results from preclinical studies of its TiaraTM valve for the transcatheter treatment of mitral regurgitation has been published in JACC: Cardiovascular Interventions. The review concludes that implantation of the Tiara valve is technically feasible, safe and results in a stable and well-functioning mitral bioprosthesis...
0
0
0


Storyboard
Print
Share this Article

Recommended

  • {TITLE}
    {PUBLISHER} - {PUBLISHED_DATE}
    {VIEWS}
  • Create Storyboard